Pure Global
NCT06409585

Cardiomyopathies and Heart Muscle Diseases: Cardiac Imaging in the Evaluation of Myocardial Fibrosis Transition

University of Edinburgh·ClinicalTrials.gov·diagnostic testRecruiting
View on ClinicalTrials.gov →
Study focus
Disease/Condition
Heart Failure With Preserved Ejection Fraction,Hypertrophic Cardiomyopathy,Cardiac Sarcoidosis,Hypertensive Heart Disease,Tako Tsubo Cardiomyopathy,Arrhythmogenic Right Ventricular Cardiomyopathy 1,Myocarditis
Drug/Device/Intervention
68Ga-FAPI or 18F-AlF-FAPI cardiac PET-MR
Study type
Observational
Intervention type
diagnostic test
Sponsor & location
Primary sponsor
University of Edinburgh
Location
Edinburgh, United Kingdom
Timeline & enrollment
Phase
N/A
Start date
May 01, 2023
End date
Jan 01, 2026
Enrollment
290 participants
Primary outcome

Standardised uptake values,Target-to-background ratio

Summary

Heart scarring, also known as fibrosis, plays a major role in a lot of heart muscle
 abnormalities. These abnormalities of the heart muscle can lead to major issues such as
 symptoms of heart failure, dangerous heart rhythm disturbances and even death. However, a lot
 of these conditions are still not fully understood and treatment options are limited. We here
 aim to use a new radioactive dye called 68Ga-FAPI to identify patterns and the activity of
 heart muscle scarring. This radioactive dye is being used in humans particularly in
 identifying and monitoring cancers and has shown promise in identifying scarring in the heart
 as well. This will help us not only understand the underlying disease process and risk
 stratify these patients but also potentially help us develop new targeted therapies that can
 affect heart muscle scarring. Participants will undergo a baseline MRI scan using this new
 dye and a plain MRI scan will repeated 12-18 months after to see if there are any changes in
 the process.

ICD-10 classifications
Hypertensive heart disease with (congestive) heart failureHeart failureHypertensive heart disease without (congestive) heart failureOther ill-defined heart diseasesHeart failure, unspecified
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06409585
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06409585 through Pure Global AI's free database. This phase not specified trial is sponsored by University of Edinburgh and is currently Recruiting. The study focuses on Heart Failure With Preserved Ejection Fraction,Hypertrophic Cardiomyopathy,Cardiac Sarcoidosis,Hypertensive Heart Disease,Tako Tsubo Cardiomyopathy,Arrhythmogenic Right Ventricular Cardiomyopathy 1,Myocarditis. Target enrollment is 290 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.